Pazopanib for the first-line treatment of advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA215
  • Published: 
  • Last updated: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA Group:

  • Kilonzo M, Hislop J, Elders A et al. Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma (September 2010)

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, and patient or carer groups gave their expert views on pazopanib by providing a written statement to the Committee. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • GlaxoSmithKline

Professional or specialist and patient or carer groups:

  • James Whale Fund for Kidney Cancer

  • Kidney Cancer UK

  • Macmillan Cancer Support

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Oncology Nursing Society

Other consultees:

  • Department of Health

  • NHS Waltham Forest

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Novartis

  • Pfizer

  • Aberdeen HTA

  • National Institute for Health Research Health Technology Assessment Programme

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on pazopanib by providing oral evidence to the Committee.

  • Dr Thomas Powles, Senior Lecturer and Consultant, nominated by GlaxoSmithKline and Pfizer Ltd – clinical specialist

  • Dr David Chao, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical specialist

  • Jacqueline Lowe, nominated by Kidney Cancer UK – patient expert

  • Bill Savage, patient advocate, nominated by James Whale Fund for Kidney Cancer – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • GlaxoSmithKline